Therapeutic potential of Toll-like receptor 9 activation.
about
CTLA-4 blockade: therapeutic potential in cancer treatmentsToll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responsesToll-like receptor 9-dependent immune activation by unmethylated CpG motifs in Aspergillus fumigatus DNAVaccine adjuvants as potential cancer immunotherapeuticsTargeted drugs in small-cell lung cancerPrimary cutaneous lymphomas: diagnosis and treatmentThe Yin and Yang of Toll-like receptors in cancerSteps to translate preconditioning from basic research to the clinicStructure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery systemTrial watch: Dendritic cell-based anticancer therapyEpithelial toll-like receptor 9 signaling in colorectal inflammation and cancer: clinico-pathogenic aspectsRecent advances of vaccine adjuvants for infectious diseasesCpG oligodeoxynucleotides as mucosal adjuvantsEarly experience with novel immunomodulators for cancer treatmentProgress toward in vivo use of siRNAs-IIMonoclonal antibodies and other biologic agents in the treatment of asthmaThe Roles of Mitochondrial Damage-Associated Molecular Patterns in DiseasesCpG-ODN attenuates pathological cardiac hypertrophy and heart failure by activation of PI3Kα-Akt signalingComparative proteomics study reveals that bacterial CpG motifs induce tumor cell autophagy in vitro and in vivoAn in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapySynergistic TLR2/6 and TLR9 activation protects mice against lethal influenza pneumoniaImmunization with a hemagglutinin-derived synthetic peptide formulated with a CpG-DNA-liposome complex induced protection against lethal influenza virus infection in mice.A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost.Post-traumatic anxiety associates with failure of the innate immune receptor TLR9 to evade the pro-inflammatory NFκB pathway.Aptamers and their biological applicationsCD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions.Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid {beta} neurotoxicity in in vitro and in vivo models of Alzheimer's disease.A naturally occurring variant in human TLR9, P99L, is associated with loss of CpG oligonucleotide responsiveness.Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist.Labeling and functionalizing amphipols for biological applications.Immunogenomics and systems biology of vaccines.Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes.Sequence-non-specific effects of RNA interference triggers and microRNA regulators.DNA from Porphyromonas gingivalis and Tannerella forsythia induce cytokine production in human monocytic cell lines.Pathogen recognition receptors, cancer and inflammation in the gut.Defective plasmacytoid dendritic cell-NK cell cross-talk in HIV infection.Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity.pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides.The Use of Xanthan Gum as Vaccine Adjuvant: An Evaluation of Immunostimulatory Potential in BALB/c Mice and Cytotoxicity In Vitro.Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release.
P2860
Q24622666-EF9ADFF5-3F92-49BA-B29E-AB08F56E3A66Q24624348-C8ABF757-2263-46E1-A51B-BFCFF8E9C59FQ24656078-05259EF5-EF50-4BB8-8BAC-B23A0E35365AQ26752522-EF250321-121F-4686-A6C7-7F7E5A5B5857Q26767017-B3035AA1-8635-4E9C-9860-B31E6B16DF11Q26772207-AC86930D-70F3-48AC-8C40-6ED4A81AE782Q26851526-867D3252-DC07-4ADE-A60B-E29109D08449Q26995931-3295391C-76B1-4CB4-ABC7-F3C248FF027DQ27004381-89B97E35-B155-496A-AD94-B22CC7276E02Q27024047-461845E8-B90C-4781-BAC5-7C147CD9BC11Q27025290-24CD2C97-3A71-4AA2-AEC5-E4276AA5A2B9Q28083679-0B49A19A-6EAE-4FEF-97DB-98872EA7CFE8Q28086998-63DEFB22-616C-4045-AE60-D545F9195736Q28241744-6A478AD8-BCB9-4A8F-8342-D43FBD3687FEQ28255877-5C77D84F-8451-429D-9457-020D29301BC0Q28270037-830CBF00-D8D3-4392-B277-3FA6B2217E9AQ28396823-8478CFA7-C464-4E6F-8807-92C2B9EB27E6Q28487365-2B6EE263-25CF-4615-A0BB-9AA3B25B96B7Q28582844-08F13913-1D29-463F-A73D-E1DAFAE66908Q28729093-ECF8BFFB-6F70-48AF-B8E4-61F621563A2EQ28732374-F21CAF5C-AD74-48A0-8534-F558CBEE3EB5Q30423481-84320F88-2C1E-439B-B123-27A0AC91913AQ30445071-497C34A0-35EF-476A-A57A-522DEDC179A6Q30468802-EA9931B2-4245-4615-9FC5-8623546DAC6CQ30470240-70B750FA-6B74-45C7-A0E0-6122A556D731Q30490447-A46D5EFB-E154-4AA0-AEA5-676538E0D0C0Q30491484-5B3110D1-6589-4893-BB88-FC9CF0A3F331Q30497349-D47D07E7-40A2-4076-BA9B-4DA70E2E7E4BQ30573156-C7E6EF7D-629E-4DE2-92EA-85E893FBD7C7Q30792341-C1184504-7E9E-4829-8066-27D6B575915EQ33350387-6831B517-4985-4A52-9963-D4FEF6579651Q33353872-0DD533C6-5C95-4C69-ACBB-D9B1BD915DBDQ33566425-3C4EAA58-3D1A-4FAC-BC38-6474EDD114F9Q33595884-01163236-D060-42BD-882F-A202CA571654Q33680511-BB285246-470B-4F14-B893-5BD55768D6D3Q33686528-846D2944-A4B1-4A1D-B432-83A439D1735DQ33690978-B582FFF8-356B-4A5B-A16A-E014A9C614DEQ33703757-C1AE38D6-6908-4504-9E2C-0109AB731E4EQ33710401-821F93C9-1136-4929-ADC5-82812A17D215Q33760871-EBBD3F7E-83AD-4100-94D0-BA31EC3CC401
P2860
Therapeutic potential of Toll-like receptor 9 activation.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Therapeutic potential of Toll-like receptor 9 activation.
@ast
Therapeutic potential of Toll-like receptor 9 activation.
@en
type
label
Therapeutic potential of Toll-like receptor 9 activation.
@ast
Therapeutic potential of Toll-like receptor 9 activation.
@en
prefLabel
Therapeutic potential of Toll-like receptor 9 activation.
@ast
Therapeutic potential of Toll-like receptor 9 activation.
@en
P356
P1476
Therapeutic potential of Toll-like receptor 9 activation.
@en
P2093
Arthur M Krieg
P2888
P304
P356
10.1038/NRD2059
P577
2006-06-01T00:00:00Z
P5875
P6179
1018394979